Intersect ENT stock plunges 25% on disappointing earnings

Intersect ENT's stock plunged almost 25% after the maker of bioresorbable drug-eluting implants for conditions of the ear, nose and throat reported a loss of $9.7 million on sales of $14.2 million. The financials were below expectations; the loss increased 65.5% year over year. More on its earnings

Suggested Articles

Battelle received an emergency go-ahead from the FDA over the weekend to deploy its decontamination system for N95 respirator masks.

The limited supply of ventilators is one of the chief concerns facing hospitals as they prepare for more COVID-19 cases.

In one of the longest studies to date in high-risk heart disease, researchers found no significant difference in death rates over more than 10 years.